RE:RE: Deutsche Bank Initiates Coverage on Acumen Pharmaceuticals I think that the issue is more that they have not wanted to sell or lose control. Big pharma is letting them sweat and melt down and will gladly scoop up the patents if they go under.
This is Cashman's baby. My thinking is he'd rather muddle through slowly than sell for below what it is worth or lose control. And if their hypothesis continues to pan out, it is worth a whole lot.
The annoying part to me is the high salaries of management, given the fiscal situation. I think they'll get PMN310 to Phase 3 in the next five years, but we'll get diluted significantly through that process.
As to delisting, that would be unfortunate. Yet another reason they need to market their unique product and get the pps back up.
Hopefully with ABOS rising, we'll follow suit. I think the PMN market cap is ridiculously low, given the AD market and the preclinical data.